SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase...
Read More Details
Finally We wish PressBee provided you with enough information of ( Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer )
Also on site :
- ‘Sopranos’ and ‘The Wire’ Actor Dies at 84
- I Took Magnesium Before Bed for 6 Months and It Completely Transformed My Sleep
- CHP: Berkeley streets put on lockdown after suspect throws live grenade